Elan (ELN) flies 8.3% premarket after investors approve a $200M share repurchase plan, meaning...

|About: Elan Corporation, plc (ELN)|By:, SA News Editor

Elan (ELN) flies 8.3% premarket after investors approve a $200M share repurchase plan, meaning Royalty Pharma's bid for the company has now lapsed, freeing Elan to seek other buyers. Also rejected is a deal with Theravance (THRX) and the acquisition of AOP Orphan Pharmaceuticals.